# A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

> **NCT05885464** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beam Therapeutics Inc.** · enrollment: 5 (actual)

## Conditions studied

- Lymphoblastic Lymphoma
- T-Cell Lymphoblastic Leukemia/Lymphoma
- Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** BEAM-201

## Key facts

- **NCT ID:** NCT05885464
- **Lead sponsor:** Beam Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-25
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05885464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05885464, "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05885464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*